US FDA issues CRL to Hikma ’s generic version of GSK’s Advair Diskus

Hikma Pharmaceuticals has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the abbreviated new drug application (ANDA) of its generic version of GlaxoSmithKline's Advair Diskus (fluticasone propionate and s …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news